Brand Name

Folotyn

Generic Name
Pralatrexate
View Brand Information
FDA approval date: September 24, 2009
Classification: Folate Analog Metabolic Inhibitor
Form: Injection

What is Folotyn (Pralatrexate)?

FOLOTYN is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma . This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. FOLOTYN is a dihydrofolate reductase inhibitor indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma . This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

Approved To Treat

Top Global Experts

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

Pilot Study Using Induction Chemo-immunotherapy Followed by Consolidation With Reduced Toxicity Conditioning and Allogenic Stem Cell Transplant in Advanced Stage Mature Non-anaplastic T-Cell or NK Lymphoma/Leukemia in Children, Adolescents and Young Adults; A NK/T-Cell Lymphoma/Leukemia Consortium Study
Pilot Study Using Induction Chemo-immunotherapy Followed by Consolidation With Reduced Toxicity Conditioning and Allogenic Stem Cell Transplant in Advanced Stage Mature Non-anaplastic T-Cell or NK Lymphoma/Leukemia in Children, Adolescents and Young Adults; A NK/T-Cell Lymphoma/Leukemia Consortium Study
Who is this study for: Patients with advanced stage mature non-anaplastic T-cell or NK lymphoma/leukemia
Enrollment Status: Recruiting
Publish Date: August 18, 2026
Intervention Type: Drug
Study Drugs: Methotrexate, Pralatraxate, Ifosfamide, Dexamethasone, Etoposide, Calaspargase pegol, Cyclophosphamide, Doxorubicin, Prednisone, Brentuximab Vedotin
Study Phase: Early Phase 1

Summary: Patients are in 2 cohorts: Cohort 1: dexamethasone, methotrexate, ifosfamide, pegaspargase, and etoposide (modified SMILE) chemotherapy regimen alone and pembrolizumab in children, adolescents, and young adults with advanced stage NK lymphoma and leukemia Cohort 2: combining pralatrexate (PRX) (Cycles 1, 2, 4, 6) and brentuximab vedotin (BV) (Cycles 3, 5) to cyclophosphamide, doxorubicin, and pred...

A Phase 3, Randomized, Open-Label Study Comparing the Efficacy and Safety of the Combination of Beleodaq-CHOP or Folotyn-COP to the CHOP Regimen Alone in Newly Diagnosed Patients With Peripheral T-Cell Lymphoma
A Phase 3, Randomized, Open-Label Study Comparing the Efficacy and Safety of the Combination of Beleodaq-CHOP or Folotyn-COP to the CHOP Regimen Alone in Newly Diagnosed Patients With Peripheral T-Cell Lymphoma
Enrollment Status: Recruiting
Publish Date: July 22, 2026
Intervention Type: Drug
Study Phase: Phase 3

Summary: Part 1: This is a 5 Arm study primarily to determine the best dose out of the two dose levels of Belinostat and Pralatrexate combined with CHOP/COP in newly diagnosed PTCL patients based on Safety for part 2 study. Part 2 (Efficacy and Safety): This is a 3 Arm study. Patients with previously untreated PTCL will be randomized 1:1:1 into 1 of 3 treatment groups: 2 experimental treatment groups (Bel-...

Pralatrexate and Bendamustine With 3 Gy TBI as a New Reduced Intensity Conditioning (RIC) Regimen for Allogeneic HCT for T-Cell Lymphoma Patients Who Are in Untreated R/R, or in Remission With MRD
Pralatrexate and Bendamustine With 3 Gy TBI as a New Reduced Intensity Conditioning (RIC) Regimen for Allogeneic HCT for T-Cell Lymphoma Patients Who Are in Untreated R/R, or in Remission With MRD
Enrollment Status: Recruiting
Publish Date: May 11, 2026
Intervention Type: Radiation, Procedure, Drug, Other
Study Phase: Phase 1/Phase 2

Summary: This phase I/II trial studies the side effects and best dose of pralatrexate in combination with bendamustine and total-body irradiation (TBI) followed by a donor stem cell transplant in treating patients with T-cell non-Hodgkin lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Pralatrexate may block the growth of can...

View All Clinical Trials

Related Latest Advances

Single-agent gemcitabine enabling successful bridging to allogeneic haematopoietic stem-cell transplantation in refractory peripheral T-cell lymphoma, not otherwise specified.
Single-agent gemcitabine enabling successful bridging to allogeneic haematopoietic stem-cell transplantation in refractory peripheral T-cell lymphoma, not otherwise specified.
Journal: BMJ case reports
Published: June 23, 2026
Pralatrexate is a potent pan-serotype human adenovirus inhibitor through suppression of dihydrofolate reductase.
Pralatrexate is a potent pan-serotype human adenovirus inhibitor through suppression of dihydrofolate reductase.
Journal: Antimicrobial agents and chemotherapy
Published: May 28, 2026
Beyond Romidepsin: Novel Therapeutic Targets and Emerging Strategies for Relapsed and Refractory Peripheral T-Cell Lymphoma.
Beyond Romidepsin: Novel Therapeutic Targets and Emerging Strategies for Relapsed and Refractory Peripheral T-Cell Lymphoma.
Journal: Clinical lymphoma, myeloma & leukemia
Published: April 21, 2026
View All Latest Advances